StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.
Bio-Path Stock Up 0.9 %
Shares of NASDAQ BPTH opened at $1.16 on Friday. Bio-Path has a 12-month low of $0.59 and a 12-month high of $12.00. The company has a 50-day moving average of $0.90 and a 200 day moving average of $1.22.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- P/E Ratio Calculation: How to Assess Stocks
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Consumer Staples Stocks, Explained
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Election Stocks: How Elections Affect the Stock Market
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
